Aligos TherapeuticsALGS
13F holders, Q4 2024 (December 31)1holders −48
1new positions
0sold out
$39.84avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings, down 48 from Q2 2024. 1 opened new positions and 0 sold out. The largest holder was Avior Wealth Management, LLC ($3K).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L105
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3K |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q4 2024: 80 shares bought, net +80 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Avior Wealth Management, LLC | 0.00% | New | 80 | $3K |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.